Physician profile
Morris Taub
NPI 1922071091
$6,913.40
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,409 · 2020: $582 · 2021: $1,804 · 2022: $1,195 · 2023: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,107.49 | 2019-2023 | Xarelto |
| Abbvie INC. | $947.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $547.26 | 2019-2022 | |
| Gilead Sciences, INC. | $435.97 | 2019-2022 | |
| Amarin Pharma, INC. | $388.54 | 2019 | |
| Allergan, INC. | $362.16 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $355.78 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $323.52 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $253.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $251.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $238.61 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $148.94 | 2023 | Stelara |
| Ferring Pharmaceuticals INC. | $141.93 | 2023 | Rebyota |
| Exact Sciences Corporation | $137.85 | 2023 | Cologuard Collection Kit |
| Csa Medical, INC | $130.99 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $123.41 | 2021 | |
| Glaxosmithkline, LLC. | $123.40 | 2021 | |
| Genzyme Corporation | $120.39 | 2022 | |
| Lucid Diagnostics INC. | $118.61 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $115.53 | 2021 | |
| Apollo Endosurgery US INC | $111.07 | 2023 | Overstitch Endoscopic Suturing System |
| Boston Scientific Corporation | $99.74 | 2020 | |
| Merck Sharp & Dohme LLC | $94.59 | 2019 | |
| Conmed Corporation | $54.64 | 2019 | |
| Covidien LP | $44.64 | 2019 | |
| Pfizer INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Taub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.